Brief: Jiangsu Recbio Technology Received Approval From Uae For Phase Ii/Iii Clinical Trial Of Sequential Booster Vaccination For Recov
13/04/2022 02:33
April 13 (Reuters) - Jiangsu Recbio Technology:
* RECEIVED APPROVAL FROM UAE FOR PHASE II/III CLINICAL TRIAL
OF
SEQUENTIAL BOOSTER VACCINATION FOR RECOV
Source text for Eikon: ID:nHKSbSrS6n
Further company coverage: 2179.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Jiangsu Recbio Technology
See all newsBrief: Jiangsu Recbio Technology To Re-Plan Timetable For HPV Vaccine Marketing Application
Brief: Jiangsu Recbio Technology Says New Drug Application For REC610 Shingles Vaccine Accepted By NMPA
Brief: Jiangsu Recbio Technology Says Liu Yong Resigned As Chair
Brief: Jiangsu Recbio Technology Says Li Bu Resigned As Executive Director
Brief: Jiangsu Recbio Technology Says Acceptance By CSRC Of Application Materials For Issuance Of Shares